Milligan Michael Lee 4
4 · Neumora Therapeutics, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Neumora Therapeutics CFO Michael Milligan Sells 1,436 Shares
What Happened Michael Lee Milligan, Chief Financial Officer & Principal Accounting Officer of Neumora Therapeutics (NMRA), disposed of 1,436 shares of common stock on 2026-02-17 in an open-market/private sale at $3.56 per share, for total proceeds of $5,119. This was a sale (not a buy) and appears to be a routine transaction to cover withholding rather than an investment purchase.
Key Details
- Transaction date and price: 2026-02-17, 1,436 shares at $3.56 each.
- Total value: $5,119.
- Shares owned after transaction: not disclosed in the filing.
- Footnote: Sale was effected under a Rule 10b5-1 trading plan adopted Aug 30, 2024 to automatically sell shares issuable on RSU vesting dates to satisfy withholding obligations.
- Filing timeliness: Report filed 2026-02-19 for a 2026-02-17 transaction (appears timely under Form 4 rules).
Context The sale was made under a pre-established 10b5-1 plan and was intended to meet tax withholding on restricted stock unit vesting, which is a common, non-discretionary reason for insiders to sell shares. Such withholding-driven sales are typically routine and do not necessarily signal a change in the insider’s view of the company.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-02-17$3.56/sh−1,436$5,119→ 21,034 total
Footnotes (1)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 30, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.